Edrecolomab in the adjuvant treatment of colorectal carcinoma

被引：2

作者：

Alliot, C ^{[1
]}

机构：

[1] Gen Hosp Annemasse, Sect Oncol, F-74107 Annemasse, France

来源：

LANCET | 2003年 / 361卷 / 9351期

关键词：

D O I：

10.1016/S0140-6736(03)12145-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：82 / 82

页数：1

共 5 条

[1] Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients [J].

Braun, S ;

Kentenich, C ;

Janni, W ;

Hepp, F ;

de Waal, J ;

Willgeroth, F ;

Sommer, H ;

Pantel, K .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :80-86

[2]

HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444

[3] Rituximab dose-escalation trial in chronic lymphocytic leukemia [J].

O'Brien, SM ;

Kantarjian, H ;

Thomas, DA ;

Giles, FJ ;

Freireich, EJ ;

Cortes, J ;

Lerner, S ;

Keating, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2165-2170

[4]

Pantel K, 1996, PROG HISTOCHEM CYTOC, V30, P1

[5] Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study [J].

Punt, CJA ;

Nagy, A ;

Douillard, JY ;

Figer, A ;

Skovsgaard, T ;

Monson, J ;

Barone, C ;

Fountzilas, G ;

Riess, H ;

Moylan, E ;

Jones, D ;

Dethling, J ;

Colman, J ;

Coward, L ;

MacGregor, S .

LANCET, 2002, 360 (9334) :671-677

← 1 →